Single Large-Scale Mitochondrial Deletion Syndromes: Neuroimaging Phenotypes and Longitudinal Progression in Pediatric Patients

References

1. 1.↵
   1. Björkman K,
   2. Vissing J,
   3. Østergaard E, et al

   . Phenotypic spectrum and clinical course of single large-scale mitochondrial DNA deletion disease in the paediatric population: a multicentre study. J Med Genet 2023;60:65–73 doi:10.1136/jmedgenet-2021-108006 pmid:34872991

   Abstract/FREE Full Text
2. 2.↵
   1. Reynolds E,
   2. Byrne M,
   3. Ganetzky R, et al

   . Pediatric single large-scale mtDNA deletion syndromes: the power of patient reported outcomes. Mol Genet Metab 2021;134:301–08 doi:10.1016/j.ymgme.2021.11.004 pmid:34862134

   CrossRefPubMed
3. 3.↵
   1. Adam MP,
   2. Feldman J,
   3. Mirzaa GM, et al.

   1. Goldstein A,
   2. Falk MJ

   . Single large-scale mitochondrial DNA deletion syndromes. 2003 Dec 17 [updated 2023 Sep 28]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301382.
4. 4.↵
   1. Broomfield A,
   2. Sweeney MG,
   3. Woodward CE, et al

   . Paediatric single mitochondrial DNA deletion disorders: an overlapping spectrum of disease. J Inherit Metab Dis 2015;38:445–57 doi:10.1007/s10545-014-9778-4 pmid:25352051

   CrossRefPubMed
5. 5.↵
   1. Gustafson MA,
   2. McCormick EM,
   3. Perera L, et al

   . Mitochondrial single-stranded DNA binding protein novel de novo SSBP1 mutation in a child with single large-scale mtDNA deletion (SLSMD) clinically manifesting as Pearson, Kearns-Sayre, and Leigh syndromes. PLoS One 2019;14:e0221829 doi:10.1371/journal.pone.0221829 pmid:31479473

   CrossRefPubMed
6. 6.↵
   1. Alves CAPF,
   2. Teixeira SR,
   3. Martin-Saavedra JS, et al

   . Pediatric Leigh syndrome: neuroimaging features and genetic correlations. Ann Neurol 2020;88:218–32 doi:10.1002/ana.25789 pmid:32445240

   CrossRefPubMed
7. 7.↵
   1. Yoshimi A,
   2. Ishikawa K,
   3. Niemeyer C, et al

   . Pearson syndrome: a multisystem mitochondrial disease with bone marrow failure. Orphanet J Rare Dis 2022;17:379 doi:10.1186/s13023-022-02538-9 pmid:36253820

   CrossRefPubMed
8. 8.↵
   1. Mancuso M,
   2. Orsucci D,
   3. Angelini C, et al

   . Redefining phenotypes associated with mitochondrial DNA single deletion. J Neurol 2015;262:1301–09 doi:10.1007/s00415-015-7710-y pmid:25808502

   CrossRefPubMed
9. 9.↵
   1. Grady JP,
   2. Campbell G,
   3. Ratnaike T, et al

   . Disease progression in patients with single, large-scale mitochondrial DNA deletions. Brain 2014;137:323–34 doi:10.1093/brain/awt321 pmid:24277717

   CrossRefPubMed
10. 10.↵
    1. Holt IJ,
    2. Harding AE,
    3. Cooper JM, et al

    . Mitochondrial myopathies: clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. Ann Neurol 1989;26:699–708 doi:10.1002/ana.410260603 pmid:2604380

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Moraes CT,
    2. DiMauro S,
    3. Zeviani M, et al

    . Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med 1989;320:1293–99 doi:10.1056/NEJM198905183202001 pmid:2541333

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Rötig A,
    2. Bourgeron T,
    3. Chretien D, et al

    . Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome. Hum Mol Genet 1995;4:1327–30 doi:10.1093/hmg/4.8.1327 pmid:7581370

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Chu BC,
    2. Terae S,
    3. Takahashi C, et al

    . MRI of the brain in the Kearns-Sayre syndrome: report of four cases and a review. Neuroradiology 1999;41:759–64 doi:10.1007/s002340050838 pmid:10552027

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Yu M,
    2. Zhang Z,
    3. Wang Q-Q, et al

    . Clinical and brain magnetic resonance imaging features in a cohort of Chinese patients with Kearns-Sayre syndrome. Chin Med J (Engl) 2016;129:1419–24 doi:10.4103/0366-6999.183417 pmid:27270536

    CrossRefPubMed
15. 15.↵
    1. Saneto RP,
    2. Friedman SD,
    3. Shaw DWW

    . Neuroimaging of mitochondrial disease. Mitochondrion 2008;8:396–413 doi:10.1016/j.mito.2008.05.003 pmid:18590986

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Alves CAPF,
    2. Zandifar A,
    3. Peterson JT, et al

    . MELAS: phenotype classification into classic-versus-atypical presentations. AJNR Am J Neuroradiol 2023;44:602–10 doi:10.3174/ajnr.A7837 pmid:37024306

    Abstract/FREE Full Text
17. 17.↵
    1. von Elm E,
    2. Altman DG,
    3. Egger M, et al

    ; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–57 doi:10.1016/S0140-6736(07)61602-X pmid:18064739

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Luca P,
    2. Alessia G,
    3. Camilla R-EM, et al

    . Spinal cord involvement in Kearns-Sayre syndrome: a neuroimaging study. Neuroradiology 2020;62:1315–21 doi:10.1007/s00234-020-02501-0 pmid:32700106

    CrossRefPubMed
19. 19.↵
    1. Balci TB,
    2. Hartley T,
    3. Xi Y, et al

    ; Care4Rare Canada Consortium. Debunking Occam’s razor: diagnosing multiple genetic diseases in families by whole-exome sequencing. Clin Genet 2017;92:281–89 doi:10.1111/cge.12987 pmid:28170084

    CrossRefPubMed
20. 20.↵
    1. van der Voorn JP,
    2. Pouwels PJW,
    3. Kamphorst W, et al

    . Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. AJNR Am J Neuroradiol 2005;26:442–46 pmid:15760847

    PubMedWeb of Science
21. 21.↵
    1. Fourati H,
    2. Ellouze E,
    3. Ahmadi M, et al

    . MRI features in 17 patients with l2 hydroxyglutaric aciduria. Eur J Radiol Open 2016;3:245–50 doi:10.1016/j.ejro.2016.09.001 pmid:27709120

    CrossRefPubMed
22. 22.↵
    1. Sferruzza G,
    2. Del Bondio A,
    3. Citterio A, et al

    . U-fiber leukoencephalopathy due to a novel mutation in the gene. Neurol Genet 2021;7:e573 doi:10.1212/NXG.0000000000000573 pmid:33709035

    Abstract/FREE Full Text
23. 23.↵
    1. Sakai Y,
    2. Kira R,
    3. Torisu H, et al

    . Persistent diffusion abnormalities in the brainstem of three children with mitochondrial diseases. AJNR Am J Neuroradiol 2006;27:1924–26 pmid:17032867

    PubMedWeb of Science
24. 24.↵
    1. Brown GK,
    2. Squier MV

    . Neuropathology and pathogenesis of mitochondrial diseases. J Inherit Metab Dis 1996;19:553–72 doi:10.1007/BF01799116 pmid:8884579

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Alves CAPF,
    2. Goldstein A,
    3. Teixeira SR, et al

    . Involvement of the spinal cord in primary mitochondrial disorders: a neuroimaging mimicker of inflammation and ischemia in children. AJNR Am J Neuroradiol 2021;42:389–96 doi:10.3174/ajnr.A6910 pmid:33384291

    Abstract/FREE Full Text
26. 26.↵
    1. Parikh S,
    2. Saneto R,
    3. Falk MJ, et al

    . A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol 2009;11:414–30 doi:10.1007/s11940-009-0046-0 pmid:19891905

    CrossRefPubMed
27. 27.↵
    1. Rossi-Espagnet MC,
    2. Lucignani M,
    3. Pasquini L, et al

    . Visual pathways evaluation in Kearns Sayre syndrome: a diffusion tensor imaging study. Neuroradiology 2020;62:241–49 doi:10.1007/s00234-019-02302-0 pmid:31680196

    CrossRefPubMed
28. 28.↵
    1. Mancuso M, and
    2. Klopstock T.

    1. Alves CAPF,
    2. Teixeira SR,
    3. Goncalves FG, et al

    . Neuroimaging findings in primary mitochondrial cytopathies. In: Diagnosis and Management of Mitochondrial Disorders. Eds: Mancuso M, and Klopstock T. Springer-Verlag International Publishing; 2019:289–316
29. 29.↵
    1. Gonçalves FG,
    2. Alves CAPF,
    3. Heuer B, et al

    . Primary mitochondrial disorders of the pediatric central nervous system: neuroimaging findings. Radiographics 2020;40:2042–67 doi:10.1148/rg.2020200052 pmid:33136487

    CrossRefPubMed